ClearPoint Neuro Reports $12.1 Million in Third-Quarter 2026 Revenue
ClearPoint Neuro reported $12.1 million in third-quarter 2026 revenue, while neurosurgery navigation and therapy revenue increased 59% to $5.4 million.
ClearPoint Neuro, Inc. (NASDAQ:CLPT) reported third-quarter 2026 revenue of $12.1 million for the period ended September 30, 2026, an increase of 36% from the same quarter in 2025. The results included contributions from the IRRA flow portfolio acquired through the company’s acquisition of IRRAS in the fourth quarter of 2025.
Neurosurgery navigation and therapy revenue rose 59% to $5.4 million. This category includes navigation, laser, drill and IRRA flow products, with the company attributing the increase primarily to sales of IRRA flow.
Biologics and drug delivery revenue increased 11% to $4.9 million from $4.4 million a year earlier. ClearPoint Neuro said the change was mainly linked to higher revenue from services delivered at ClearPoint Advanced Laboratories.
Capital equipment and software revenue reached $1.7 million, up from $1.0 million in the comparable period. The company attributed the increase mainly to placements of ClearPoint navigation capital and software, IRRA flow control units and Prism laser units.
Gross margin was 58% in the third quarter, compared with 63% in the same period of 2025. ClearPoint Neuro said the decline was primarily caused by overhead at the new ClearPoint Advanced Laboratories facility and additional amortisation expense related to acquired intangible assets. A decrease in other cost of revenue partly offset those factors.
Operating expenses increased 23% to $13.4 million from $10.9 million. The company linked the increase mainly to the IRRAS acquisition, higher personnel costs associated with expanded clinical and sales teams, and increased occupancy and travel costs.
ClearPoint Neuro reported cash and cash equivalents of $46.2 million as of September 30, 2026, compared with $45.9 million at December 31, 2025. The company said the change reflected $22.0 million in net proceeds from its at-the-market equity offering programme, partly offset by $20.1 million used in operating activities.
For the first nine months of 2026, the cash-flow statement recorded 22,020 in net proceeds from common stock issued under the at-the-market equity offering programme, after issuance costs of $0.5 million.
ClearPoint Neuro said one partner submitted its first formal BLA for a Huntington's Disease treatment. The company also reported that it is an industry partner in a five-year, $2.98 million NCI R01 led by Dartmouth Health. The programme is intended to advance MR-guided laser therapy for spinal metastases and includes work from benchtop testing through large subject validation to a clinical trial using the ClearPoint Prism system.
ClearPoint Neuro’s role includes technical work, software development and procedural expertise. The company described the programme as early-stage research supporting its spine LITT roadmap. The research is supported by the National Cancer Institute of the National Institutes of Health under award number R01CA307001. The source states that $633,819, or 100 percent of the first-year project budget, is financed with federal funds, with no non-governmental funds included in the approved budget.
ClearPoint Neuro now estimates 2026 revenue to be between $48.0 million and $50.0 million. The company identifies this estimate as a forward-looking statement subject to risks including market adoption, the timing and outcome of partner clinical trials and regulatory submissions, partner relationships, the ability of ClearPoint Advanced Laboratories to achieve or maintain GLP compliance or generate revenue on anticipated timelines, the integration of acquired businesses including IRRAS, changes in regulation, reimbursement and funding, competition, supply chain disruptions, the ability to fund operations and service indebtedness, and general economic, market and geopolitical conditions.
ClearPoint Neuro develops device, cell and gene therapy-enabling products and services for navigation to the brain and spine. Its activities include clinical products and preclinical development services for controlled drug and device delivery. The company works with healthcare and research centres, pharmaceutical and biotech companies, academic centres and contract research organisations.
Third-quarter revenue was $12.1 million, up 36% from $8.9 million in the same period of 2025.
Neurosurgery navigation and therapy revenue increased 59% to $5.4 million.
Biologics and drug delivery revenue rose 11% to $4.9 million, while capital equipment and software revenue reached $1.7 million.
Cash and cash equivalents stood at $46.2 million at September 30, 2026, following $22.0 million in net proceeds from the at-the-market equity offering programme.
The company estimates 2026 revenue between $48.0 million and $50.0 million, subject to the risks identified in its forward-looking statements.
ClearPoint Neuro announced financial results for its third quarter ended September 30, 2026. The company reported $12.1 million in quarterly revenue, 36% overall growth, and developments including a partner’s first formal BLA submission for Huntington’s Disease and participation in a five-year, $2.98 million NCI R01 programme.
ClearPoint Neuro trades on NASDAQ under the ticker symbol CLPT, written in the source as NASDAQ:CLPT.
ClearPoint Neuro reported total revenue of $12.1 million for the three months ended September 30, 2026. This was an increase of $3.2 million, or 36%, from $8.9 million for the three months ended September 30, 2025.
Neurosurgery navigation and therapy revenue increased 59% to $5.4 million, primarily due to sales of the IRRA flow product acquired through the IRRAS acquisition. Biologics and drug delivery revenue increased 11% to $4.9 million, while capital equipment and software revenue increased 68% to $1.7 million, driven primarily by increased placements of ClearPoint navigation capital and software, IRRA flow control units and Prism laser units.
ClearPoint Neuro reported a gross margin of 58% for the three months ended September 30, 2026, compared with 63% in the same period in 2025. Operating expenses increased 23% to $13.4 million from $10.9 million, mainly because of the IRRAS acquisition, higher personnel costs, and increased occupancy and travel costs.
ClearPoint Neuro said the decrease was primarily due to overhead costs at the new ClearPoint Advanced Laboratories facility and additional amortisation expense for acquired intangible assets. These factors were partially offset by a decrease in other cost of revenue.
ClearPoint Neuro reported cash and cash equivalents of $46.2 million as of September 30, 2026, compared with $45.9 million at December 31, 2025. The company said the increase resulted from $22.0 million in net proceeds from its at-the-market equity offering programme, partially offset by $20.1 million used in operating activities.
ClearPoint Neuro received $22.0 million in net proceeds from its at-the-market equity offering programme. The cash-flow statement reports proceeds of 22,020 from the issuance of common stock under that programme, net of issuance costs of $0.5 million.
ClearPoint Neuro now estimates 2026 revenue to be between $48.0 million and $50.0 million. The company identifies this estimate and other expectations regarding future financial performance as forward-looking statements subject to business, regulatory, funding, integration and other risks.
Joe Burnett, President and CEO of ClearPoint Neuro, said the acceleration in financial performance was driven by core organic clinical product revenue and biologics and drug delivery revenue returning to double-digit growth. He also said the completion of the IRRA flow product integration had enabled improved operating leverage, while operating expenses grew 23% compared with 36% revenue growth.
ClearPoint Neuro is a device, cell and gene therapy-enabling company offering precise navigation to the brain and spine. It provides established clinical products and preclinical development services for controlled drug and device delivery, including the ClearPoint Neuro Navigation System, and works with healthcare and research centres, pharmaceutical and biotech companies, academic centres and contract research organisations.
ClearPoint Neuro is an industry partner in a five-year, $2.98 million competitively awarded NCI R01 led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases. The early-stage programme runs from benchtop through large subject validation to a clinical trial using the ClearPoint Prism system, with ClearPoint contributing technical, software development and procedural expertise.
ClearPoint Neuro reported that one partner had submitted its first formal BLA for the treatment of Huntington’s Disease. The company also said its biologics and drug delivery partners’ regulatory progress is among the matters covered by its forward-looking statements and related risks.
ClearPoint Neuro scheduled a live broadcast review of its third-quarter 2026 results for Wednesday, October 28, 2026, at 4:30 p.m. Eastern time, or 1:30 p.m. Pacific time. The source said a replay would be available shortly after the call until November 27, 2026.